Figure 2.
Prognostic effect of sAML-like gene mutations. (A) EFS according to the 3 ELN-2017 risk subgroups (P < .001). At 2 years, EFS was estimated at 42.6% (95% CI, 34.3%-50.8%), 31.8% (95% CI, 24.7%-39.2%), and 15.2% (95% CI, 10.6%-20.6%) in the favorable-, intermediate-, and adverse-risk subgroups, respectively. At 4 years, EFS was estimated at 34.8% (95% CI, 26.7%-43.1%), 21.8% (95% CI, 15.2%-29.2%), and 10.3% (95% CI, 6.0%-16.1%) in the favorable-, intermediate-, and adverse-risk, respectively. (B) EFS according to sAML-like mutations in the ELN-2017 intermediate-risk subgroup. The presence of sAML-like gene mutations significantly influenced EFS in the ELN-2017 intermediate-risk subgroup (HR, 1.52; 95% CI, 1.01-2.28; P = .044). (C) EFS according to the newly defined high-risk/standard-risk groups. EFS was significantly reduced in the high-risk group (HR, 2.03; 95% CI, 1.65-2.48; P < .001). At 2 years, EFS was estimated at 39.8% (95% CI, 33.7-45.9) in the standard-risk group compared with 16.4% (95% CI, 12.0%-21.3%) in the high-risk group. At 4 years, EFS was estimated at 29.6% (95% CI, 23.6%-35.8%) in the standard-risk group compared with 12.3% (95% CI, 8.2%-17.2%) in the high-risk group. (D) OS according to the 3 ELN-2017 risk subgroups (P < .001). At 2 years, OS was estimated at 60.3% (95% CI, 51.6%-68.0%), 50.1% (95% CI, 42.0%-57.6%), and 32.8% (95% CI, 26.4%-39.4%) in the favorable-, intermediate-, and adverse-risk subgroups, respectively. At 4 years, OS was estimated at 49.8% (95% CI, 41.0%-58.0%), 32.7% (95% CI, 24.9%-40.7%), and 16.2% (95% CI, 10.7%-22.6%) in the favorable-, intermediate-, and adverse-risk subgroups, respectively. (E) OS according to sAML-like mutations in the ELN-2017 intermediate-risk subgroup. The presence of sAML-like gene mutations did not significantly influence OS in the ELN-2017 intermediate-risk subgroup (HR, 1.31; 95% CI, 0.85-2.03; P = .22). (F) OS according to the newly defined high-risk/standard-risk groups. OS was significantly reduced in the high-risk group (HR, 1.86; 95% CI, 1.49-2.31; P < .001). At 2 years, OS was estimated at 57.6% (95% CI, 51.2%-63.5%) in the standard-risk group compared with 34.2% (95% CI, 28.3%-40.2%) in the high-risk group. At 4 years, OS was estimated at 42.9% (95% CI, 36.3%-49.3%) in the standard-risk group compared with 19.0% (95% CI, 13.8%-24.7%) in the high-risk group.

Prognostic effect of sAML-like gene mutations. (A) EFS according to the 3 ELN-2017 risk subgroups (P < .001). At 2 years, EFS was estimated at 42.6% (95% CI, 34.3%-50.8%), 31.8% (95% CI, 24.7%-39.2%), and 15.2% (95% CI, 10.6%-20.6%) in the favorable-, intermediate-, and adverse-risk subgroups, respectively. At 4 years, EFS was estimated at 34.8% (95% CI, 26.7%-43.1%), 21.8% (95% CI, 15.2%-29.2%), and 10.3% (95% CI, 6.0%-16.1%) in the favorable-, intermediate-, and adverse-risk, respectively. (B) EFS according to sAML-like mutations in the ELN-2017 intermediate-risk subgroup. The presence of sAML-like gene mutations significantly influenced EFS in the ELN-2017 intermediate-risk subgroup (HR, 1.52; 95% CI, 1.01-2.28; P = .044). (C) EFS according to the newly defined high-risk/standard-risk groups. EFS was significantly reduced in the high-risk group (HR, 2.03; 95% CI, 1.65-2.48; P < .001). At 2 years, EFS was estimated at 39.8% (95% CI, 33.7-45.9) in the standard-risk group compared with 16.4% (95% CI, 12.0%-21.3%) in the high-risk group. At 4 years, EFS was estimated at 29.6% (95% CI, 23.6%-35.8%) in the standard-risk group compared with 12.3% (95% CI, 8.2%-17.2%) in the high-risk group. (D) OS according to the 3 ELN-2017 risk subgroups (P < .001). At 2 years, OS was estimated at 60.3% (95% CI, 51.6%-68.0%), 50.1% (95% CI, 42.0%-57.6%), and 32.8% (95% CI, 26.4%-39.4%) in the favorable-, intermediate-, and adverse-risk subgroups, respectively. At 4 years, OS was estimated at 49.8% (95% CI, 41.0%-58.0%), 32.7% (95% CI, 24.9%-40.7%), and 16.2% (95% CI, 10.7%-22.6%) in the favorable-, intermediate-, and adverse-risk subgroups, respectively. (E) OS according to sAML-like mutations in the ELN-2017 intermediate-risk subgroup. The presence of sAML-like gene mutations did not significantly influence OS in the ELN-2017 intermediate-risk subgroup (HR, 1.31; 95% CI, 0.85-2.03; P = .22). (F) OS according to the newly defined high-risk/standard-risk groups. OS was significantly reduced in the high-risk group (HR, 1.86; 95% CI, 1.49-2.31; P < .001). At 2 years, OS was estimated at 57.6% (95% CI, 51.2%-63.5%) in the standard-risk group compared with 34.2% (95% CI, 28.3%-40.2%) in the high-risk group. At 4 years, OS was estimated at 42.9% (95% CI, 36.3%-49.3%) in the standard-risk group compared with 19.0% (95% CI, 13.8%-24.7%) in the high-risk group.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal